End-stage renal disease (ESRD) patients are at high risk for coronary artery disease (CAD). The optimal revascularization strategy remains unknown. We performed a meta-analysis of retrospective observational trials to compare coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) for ESRD patients with CAD. A search of published reports was conducted to identify clinical studies comparing CABG with PCI in ESRD patients with CAD with a minimal follow-up of 12 months. Sixteen studies included 32 350 ESRD patients with revascularization. Compared with PCI, CABG was associated with a lower risk for late mortality [relative risk (RR) 0.90, 95% confidence interval (CI) 0.87-0.93], myocardial infarction event (RR 0.64, 95% CI: 0.61-0.68), repeat revascularization event (RR 0.22, 95% CI: 0.16-0.31) and cumulative events (RR 0.69, 95% CI: 0.65-0.73), despite having a higher risk for early mortality (RR 1.98, 95% CI: 1.51-2.60). In conclusion, the long-term results of PCI in ESRD patients are dismal, and CABG is significantly superior to PCI in this subset of patients.
INTRODUCTION
Worldwide, the incidence of end-stage renal disease (ESRD) is high and increasing [1] [2] [3] . Among the factors determining life prognosis for ESRD patients, the most important single contributor is cardiovascular events, especially coronary artery disease (CAD). The annual report of the US Renal Date system indicated that cardiac disease accounts for 44% of all-cause mortality in dialysis patients, and approximately 22% of mortality from a cardiac cause is attributed to myocardial infarction (MI) [4] . Therefore, guidelines for coronary revascularization for this subset of patients are essential.
Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are the alternative approaches for coronary revascularization in ESRD patients with CAD. Some studies revealed that in dialysis patients PCI had a decreased risk of complications, with the disadvantages of a high restenosis rate and increased cardiac events, whereas CABG had high operative morbidity and mortality, with the advantage of long-term survival [5] [6] [7] . However, Crawford et al. reported that CABG had no influence on the aggressive atherosclerosis in dialysis patients, and the duration of patency of late vein grafts in the subset of patients might be decreased in comparison with the control group [8] . Agirbasli et al. found that dialysis patients undergoing CABG showed no statistical difference in 1 year mortality compared with those undergoing percutaneous transluminal coronary rotational angioplasty (PTCA; 27 vs 23%) [9] . Furthermore, Ashrith et al. indicated that among ESRD patients with CAD, there was no statistically significant difference in repeat revascularization rate at 30 days and long-term survival rate between a group treated with a drug-eluting stent and a CABG group (1.9 vs 0%, 62 vs 71%, respectively) [10] . It has been highlighted that the optimal method for coronary revascularization in ESRD patients remains to be determined; therefore, we performed a meta-analysis of available clinical trials that compared coronary revascularization with CABG vs PCI for CAD in ESRD patients, in order to obtain a better insight into the optimal method for coronary revascularization of ESRD patients with CAD.
Moreover, the references of all relevant articles and reviews were screened and identified.
The studies were included in this meta-analysis if they met the following predetermined criteria. (i) Studies published in an English language journal with full available text and presentations at major national cardiology meetings in English were retrieved. We also included abstracts and unpublished studies if sufficient data were reported to calculate a relative risk for ESRD patients receiving CABG compared with those receiving PCI. (ii) Trials comparing the efficacy of CABG with that of PCI in ERSD patients with CAD. The revascularization method was selected by cardiac surgeons and cardiologists experienced in interventional treatment. CABG was performed with an on-pump or off-pump procedure. Saphenous vein graft or grafts of arteries, such as the internal thoracic artery and gastroepiploic artery, were employed to achieve complete revascularization. 'Patients success' in the CABG group was defined as graft patency of more than one lesion bypassed without a major procedural complication, including death, acute MI or emergency CABG. Graft patency was defined as an extent of stenosis of the graft of <25%. PCI included PTCA and the use of bare metal stents and drug-eluting stents. 'Lesion success' in the PCI group was defined as a significant stenosis being reduced to a residual stenosis of 50%; 'patients success' was defined in a similar manner to that for CABG. Restenosis was defined as stenosis of >50% during follow-up. (iii) Trials reported at least one relevant clinical outcome, including mortality, MI or revascularization. (iv) The follow-up of each trial had a duration of ≥12 months. Studies were excluded if ESRD patients had received renal transplantation therapy before revascularization. Studies with ESRD patients receiving combination surgery, such as valve replacement surgery and CABG, were also excluded. In addition, we excluded those studies in which the relevant clinical outcomes for ESRD patients who underwent coronary revascularization were not reported.
The primary outcomes of interest in this meta-analysis were as follows (i) Mortality, including early mortality and late mortality; early mortality was defined as intra-or postoperative deaths during the same hospital admission or within 30 days after surgery, and late mortality was defined as death from any cause during the follow-up period (at least 1 year). (ii) MI, including non-Q-wave MI and Q-wave MI. (iii) Revascularization, which was was defined by the need for surgical or percutaneous intervention. It also included failure after an initial successful attempt at revascularization (i.e. graft failure with CABG or restenosis with PCI). (iv) Cumulative events, including morality, MI or repeat revascularization.
Two independent investigators assessed eligibility and abstracted the data in a standardized manner. Extracted data included the first author of the study, baseline characteristics, cardiac parameters, sample size, surgical methods, clinical outcomes and length of follow-up. Discrepancies between reviewers were resolved by discussion. If the data of study design or clinical outcome in the relevant articles were incomplete or unclear, the primary authors of these studies were contacted. An eligible clinical trial was excluded from analysis the outcome parameters if the particular parameter was not reported in the trial.
Statistical analysis
Analysis of the abstracted data was completed using Review Manager, version 5.0 for Windows. The most suitable effect index to estimate efficacy of CABG and PCI in ESRD patients with CAD was risk ratio (RR) and its 95% confidence limits (CI). We assumed PCI as the gold standard and CABG as the challenging strategy (RR > 1 favours PCI, whereas RR < 1 favours CABG). We estimated the number of events from the graphed survival curves when no other information was provide in comparison groups [11] . This was apt to overestimate the number of events but would not affect the comparison (risk ratio) between CABG and PCI in ESRD patients with CAD. Estimated ratios and their variances were applied to construct summary 95% confidence intervals for the parameters of interest for individual studies and for the summary measure. The summary estimators of treatment effect were calculated using a fixed-effects model and a random-effects model. A P-value of 0.05 or less was considered as significant. We used a fixed-effects model of meta-analysis to aggregate the study-level data, owing to homogeneity among the included studies. A random-effects model was used if heterogeneity existed among studies. The heterogeneity between the selected studies was assessed by the Q test and I 2 statistic. An I 2 value <30% was regarded as mild heterogeneity, 31-50% as moderate, and >50% as notable heterogeneity [12] . To evaluate sources of heterogeneity, sensitivity analyses were performed as follows: (i) including individual studies with more than 100 patients; (ii) including only subgroups with large database analyses; (iii) excluding subgroups with large database analyses; (iv) excluding subgroups that abstracted data from abstracts; and (v) excluding subgroups that abstracted data from large databases and abstracts. Forest plots were made for graphical presentations for end-points. The Egger weighted regression statistic was used to examine the publication bias, using Stata version 10.0; a P-value < 0.05 indicated that there was significant publication bias among the included studies. We considered the correlation between outcomes and the following demographics factors: mean age; proportion of patients who were female; percentage with hyperlipidaemia; percentage of smokers; percentage with previous MI; percentage with hypertension; percentage with diabetes mellitus; percentage with angina pectoris; mean ejection fraction; percentage with single-vessel CAD; percentage with multivessel CAD; percentage with left main disease; and percentage with family history of cardiovascular disease. Continuous variables in baseline demographics were analysed using weighted means, and binary variables were analysed through weighted proportions. SPSS version 13.0 was used as ancillary software to compute P-values comparing the baseline covariates between two groups by means of two-sample Student's t-test for continuous data and chi-squared tests for categorical data. All P-values were two tailed, and P < 0.05 was regarded as statistically significant.
RESULTS
A total of 3551 citations were screened between January 1990 and December 2010 by the initial search strategy. However, 3519 relevant reports were excluded on the basis of duplication and examination of the titles and/or abstracts. Thirty-two studies were retrieved for detailed evaluation. After detailed evaluation, 16 studies met our criteria for inclusion and were identified for this meta-analysis ( Fig. 1 and Table 1 ). A total of 32 350 ESRD patients were included in the analysis, with 15 156 patients who underwent CABG and 17 194 patients who underwent PCI. All 16 studies were retrospective observational trials, and a large proportion of patients were in two studies [6, 13] . Three studies described the consecutive recruitment of patients [10, 14, 15] . The mean follow-up time was 19 months. All trials reported on dialysis being performed on those patients before revascularization, although the specific modality of dialysis was not always reported. On average, the duration of dialysis was 45 months.
To identify possible significance between groups, the prevalence of pooled patients before revascularization was calculated for age [ The proportions of male patients, hypertension, multivessel coronary artery disease and left main disease were high in patients underwent CABG, while diabetes mellitus and singlevessel coronary artery disease were common in patients receiving PCI. Of these 16 studies, 14 reported early mortality data, of which nine studies showed intra-or postoperative mortality during the same hospital admission [6, 7, 9, [13] [14] [15] [16] [17] [18] , five studies indicated 30 day mortality [10, [19] [20] [21] [22] , 15 reported the data of late mortality and seven reported the MI event individually. In addition, there were seven studies reporting the repeat revascularization event separately. There were for studies [18, 19, 20, 22] for which we obtained the data from the abstract.
There was notable heterogeneity among studies for early mortality. The chi-squared test with 11 degrees of freedom (d.f.) for the Q statistic was 28.41, and I 2 value was 61%. Therefore, a random-effects model was used to analyse the heterogeneity, and the result showed that ESRD patients who underwent PCI had a significantly lower risk for early mortality compared with those patients who underwent CABG (RR 1.98, 95% CI: 1.51-2.60; Table 2 ).
The test of heterogeneity among studies for late mortality showed that the Q statistic with 14 degrees of freedom and I 2 statistic were 15.82 and 12%, respectively, indicating mild heterogeneity between the studies. Using the random-effects model it was found that the risk for late mortality was significantly lower in the ESRD patients who underwent CABG compared with those patients who underwent PCI (RR 0.90, 95% CI: 0.88-0.92; Table 3 ).
There was a higher risk for MI in ESRD patients treated with PCI compared with CABG (RR 0.64, 95% CI: 0.61-0.68; Table 4 ). The chi-squared test with five degrees of freedom for the Q statistic and the I 2 statistic was 2.61 and 0%, respectively, indicating no significant heterogeneity among those studies.
The homogeneity test among those studies for repeat revascularization was significant (P = 0.003; the observed Q statistic was 19.52 and I 2 statistic 69%), indicating significant heterogeneity among the studies. Therefore, a random-effects model was employed to analyse the heterogeneity, and the result suggested that the risk for target vessel revascularization was significantly lower in the CABG group compared with the PCI group (RR 0.22, 95% CI: 0.16-0.31; Table 5 ).
Pooled analysis showed that there was significant heterogeneity among studies for cumulative events (P < 0.00001, the observed Q statistic of 118.06 and I 2 statistic of 87%). The random-effects model analysis indicated that there was a significantly higher risk of cumulative events in the PCI group (RR 0.69, 95% CI: 0.65-0.73; Table 6 ).
A sensitivity analysis was performed to assess the impact of heterogeneity on the pooled effect estimate. When studies with fewer than 100 total patients were eliminated, the pooled point estimates did not change substantially (Table 7) . Moreover, analysis of the two larger database trials [6, 13] separately also did not change the pooled point estimates substantially (Table 7) . Furthermore, analysis of the trials without data from the two larger databases, or without data from the abstracts, or without data from the two larger database and the abstracts also did not change the pooled point estimates substantially ( Table 7) . The assessment of publication bias and Egger's weighted regression statistic (P>|t| = 0.713) showed that there was no significant publication bias.
DISCUSSION
The most important finding of this meta-analysis, in which the studies included patients with ESRD and CAD assigned to CABG or PCI on the basis of cardiologists' and cardiac surgeons' clinical judgement, was that CABG continues to result in a significantly lower rate of late mortality, MI events, target vessel revascularization events and cumulative events compared with PCI. Nonetheless, there was a significantly higher risk for early mortality associated with CABG.
The most appropriate modality of coronary artery revascularization in ESRD patients remains uncertain, because few data had been published concerning such patients, and there was a lack of randomized trials on this topic. It is true that dialysisdependent patients with ESRD have a higher incidence of CAD and extremely unfavourable long-term prognosis. Raine et al. indicated that the relative risk for death as a result of cardiovascular causes in dialysis patients is 10-fold higher, and the relative risk of dying from myocardial infarction is 5-fold that of the general population [23] . This may due to dialysis-induced accelerated atherosclerosis and arteriosclerosis, and the extraordinary atherogenic environment in ESRD patients created by a combination of classical risk factors, such as diabetes mellitus, hypertension, hyperlipidaemia, renal anaemia, increased oxidative burden and further metabolic alterations [24] . PCI initially appears more attractive to these dialysis-dependent patients with CAD, because it is less invasive, requires a shorter hospital stay, and is usually associated with less morbidity and Heterogeneity: χ² = 15.82, d.f. = 14 (P = 0.32); I² = 12%. Test for overall effect: Z = 10.66 (P < 0.00001). M-H, Random is defined as pooling done using the Mantel-Haenszel random effects model.
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short-term mortality compared with CABG. According to randomized controlled trials [25, 26] , in the general population, the incidence of early mortality was 1-3% in those receiving PCI and 1-5% among those receiving CABG. Liu et al. documented that in-hospital mortality after CABG in those receiving dialysis was much higher than that in general population (11 vs 3%) [27] . Meanwhile, Many studies suggested that perioperative death after CABG in ESRD patients is about 3-fold greater than that in non-ESRD patients, and having renal failure increased by roughly 2-fold the complications of CABG, including mediastinitis and the need for prolonged mechanical ventilation [28] [29] [30] . These results reflected increased morbidity rates and prolonged intensive care unit and hospital stays among ESRD patients. Furthermore, our meta-analysis revealed that in dialysis-dependent patients with ESRD, CABG was associated with a higher rate of early mortality compared with PCI. The reason for this may be that CABG patients with ESRD have multivessel disease and/or left main disease and their vessels are extremely atherosclerotic and calcified, which puts them at risk of perioperative death. Other possible explanations are surgical risks, such as surgical manipulation of the calcified aorta, fluid shifts due to extracorporeal circulation, malfunctioning platelets, decreased left ventricular ejection fraction [29] , severe distal disease [29] , and increased cross-clamp and cardiopulmonary bypass times [31] . However, there were studies of small series of haemodialysis patients who underwent CABG, which suggested that although the occurrence of haemorrhagic complications were greater and the hospital stay longer than in the control group, the perioperative mortality Heterogeneity: χ² = 2.61, d.f. = 5 (P = 0.76); I² = 0%. Test for overall effect: Z = 15.40 (P < 0.00001). M-H, Fixed is defined as pooling done using the Mantel-Haenszel fixed effects model. Heterogeneity: χ² = 19.52, d.f. = 6 (P = 0.003); I² = 69%. Test for overall effect: Z = 8.94 (P < 0.00001). M-H, Random is defined as pooling done using the Mantel-Haenszel random effects model. in these patients reached 5-12%, a level that is generally considered acceptable [32] . Moreover, the report of Frenken and Krian [33] indicated that compared with the interventional therapy, the surgical revascularization in dialysis-dependent patients had acceptable early results. Most studies showed that in the general population with coronary diseases, long-term mortality was lower after CABG compared with PCI [34, 35] . The potential long-term benefits of CABG may be different in dialysis-dependent patients with ESRD compared with the general population, because the impact of numerous comorbidities and decreased glomerular filtration rate in ESRD patients is manifest in long-term mortality. The work of Monaco et al. showed that compared with patients having normal renal function, those patients who have a moderate degree of renal failure (serum creatinine <2.5 mg/dl) were associated with an increase in long-term mortality after CABG [36] . In a study of 5327 patients who underwent PCI, the rate of longterm mortality was significantly higher in ESRD patients than in patients whose creatinine clearance was greater than 70 ml/min [37] . The 1 year mortality rate after PCI was almost 3-fold higher in ESRD patients than in non-ESRD patients [38] . However, the trial of Manabe et al. indicated that CABG is still superior to PCI in chronic haemodialysis patients [14] . Our meta-analysis also showed a lower risk for long-term mortality in dialysisdependent patients who underwent CABG in comparison with those patients underwent PCI, which was not consistently identified in the individual studies. The risk factors associated with long-term mortality in ESRD patients after CABG were similar to those for patients without ESRD and included age, previous MI, decrease of left ventricular ejection fraction, use of the internal mammary artery graft, chronic obstructive pulmonary disease, non-ambulatory state and emergency surgery [29, 31, 39] .
Our meta-analysis revealed an increased risk for long-term cardiac events, including MI and repeat revascularization, in ESRD patients who underwent PCI. The study of Guiteras-Val et al. indicated that there was nearly twice the rate of restenosis in ESRD patients in comparison to patients with normal renal function [40] . Furthermore, Aoyama et al. reported that there was no significant difference in the restenosis rate for chronic haemodialysis patients between drug-eluting stents (DES) and bare metal stents [41] . The neointimal formation resulting in a high restenosis rate after DES was obvious in chronic haemodialysis patients [42] . A study of 17 chronic dialysis patients who underwent PTCA found that the angina pectoris after interventional therapy recurred in 12 of 15 patients within 6 months, and restenosis was evident in 26 of 32 dilated vessels by coronary angiography [43] . In comparison with non-haemodialysis patients, the incidence of cardiac events after PTCA was much higher in haemodialysis patients during the 2 year follow-up period (50 vs 15%) [44] . The restenosis in dialysis-dependent patients after PTCA may be explained by the smaller size of dilated vessels, more severe vessel injury and greater residual stenosis related to extensive coronary calcification, and an increased prothrombotic risk [45] . DES result in substantially decreased restenosis and reduced the frequency of repeat procedures after interventional therapy, offering the possibility of percutaneous revascularization in ESRD patients with CAD. In a study of 89 consecutive ESRD patients who underwent coronary Heterogeneity: χ² = 118.06, d.f. = 15 (P < 0.00001); I² = 87%. Test for overall effect: Z = 13.95 (P < 0.00001). M-H, Random is defined as pooling done using the Mantel-Haenszel random effects model.
stenting, the DES group was associated with a significant reduction in target vessel revascularization and in a composite endpoint comprising death, MI and target-vessel revascularization with 9 months [46] . In an observation study of patients who underwent DES, the rate of target vessel revascularization at 1 month was 3.1% in ESRD patients compared with 0.4% in non-ESRD patients. The target lesion revascularization was similar at 6 months between the two groups [47] . However, Scheen et al. reported that patients with diabetes mellitus as the main cause of ESRD remained at relatively high risk for restenosis after treatment of DES, suggesting that the subsequent rate of revascularization might be even higher than in patients who underwent CABG [48] . In this meta-analysis, we did include studies that compared long-term outcomes between dialysis patients who underwent CABG and those patients who underwent DES.
The present meta-analysis, summarizing published event rates from retrospective observational studies, supports the conclusion that CABG would be the preferred revascularization strategy for ESRD patients with CAD, owing to an acceptable short-term mortality and the lower risk for long-term mortality and cardiac events. The present meta-analysis provides insight into clinical outcomes for ESRD patients with CAD after two revascularization methods. In order to improve our understanding of the effectiveness of CABG vs PCI for ESRD patients with CAD further, new large randomized clinical trials are needed. These trials need to be of an adequately large size, appropriately designed and conducted, and to cover long-term follow-up. 
